Premium
Ruxolitinib for tocilizumab‐refractory severe COVID‐19 infection
Author(s) -
Innes Andrew J.,
Cook Lucy B.,
Marks Sasha,
Bataillard Edward,
CrossetteThambiah Christina,
Sivasubramaniam Gayathiri,
Apperley Jane,
Milojkovic Dragana
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16979
Subject(s) - tocilizumab , medicine , cytokine release syndrome , cytokine storm , immunology , ruxolitinib , cytokine , rheumatology , macrophage activation syndrome , refractory (planetary science) , interleukin 6 , arthritis , disease , covid-19 , bone marrow , rheumatoid arthritis , infectious disease (medical specialty) , astrobiology , myelofibrosis , physics